Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,994
Total Claims
$1.7M
Drug Cost
651
Beneficiaries
$2,663
Cost/Patient
Risk Score Breakdown 30/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
-32%
Cost per patient vs peers
$2,663 vs $3,933 avg
-54%
Brand preference vs peers
23.3% vs 51.2% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
2.1%
Opioid Rate
191
Opioid Claims
$2,317
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,044 claims · $1.5M
Generic: 6,716 claims · $169K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 153 | $167K |
| Dulaglutide | 86 | $145K |
| Semaglutide | 49 | $77K |
| Insulin Glargine,hum.Rec.Anlog | 100 | $74K |
| Insulin Aspart | 48 | $65K |
| Apixaban | 52 | $60K |
| Insulin Degludec | 50 | $49K |
| Insulin Lispro | 31 | $45K |
| Rivaroxaban | 28 | $43K |
| Insulin Degludec | 48 | $41K |
| Empagliflozin/Metformin Hcl | 21 | $41K |
| Sitagliptin Phos/Metformin Hcl | 30 | $38K |
| Mirabegron | 56 | $37K |
| Dapagliflozin Propanediol | 33 | $36K |
| Insulin Lispro | 26 | $34K |
Prescribing Profile
Patient Profile
75
Avg Age
65%
Female
1.45
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About